Mediconomics

Executive Summary

Mediconomics is a Munich-based Contract Research Organization (CRO) offering end-to-end clinical development and regulatory services for pharmaceutical, biotech, and medical device companies. Founded in 2017, the company positions itself as a flexible, scientifically-driven partner covering clinical trials (Phases I-IV), data management, regulatory affairs, pharmacovigilance, and medical writing. As a private company with no disclosed funding or valuation, Mediconomics operates in the competitive European CRO market, leveraging its full-service capabilities and scientific expertise to support drug and device lifecycle management. The company's profile suggests a focus on mid-sized sponsors seeking personalized, high-quality CRO services. Despite limited public information, Mediconomics' presence in Munich—a major biotech hub—and its comprehensive service offering position it well for steady organic growth. However, the lack of disclosed financials or client pipeline makes it challenging to assess near-term momentum. The company's success will depend on its ability to win new client contracts, retain existing partnerships, and potentially expand into adjacent therapeutic areas or geographies. Overall, Mediconomics represents a niche player in the CRO space with a stable but unremarkable outlook.

Upcoming Catalysts (preview)

• Q3 2026New strategic client contract win (e.g., Phase II/III trial)60% success
• Q4 2026Expansion of service offerings into real-world evidence or digital biomarkers40% success
• Q2 2027Partnership with a large pharmaceutical company for regulatory consulting30% success